Nymox Pharmaceutical annual return on equity
2018
2019
2020
2021
Nymox Pharmaceutical Return on Equity (ROE) Growth & History (NYMXF)
Nymox Pharmaceutical's return on equity was −1,529.84% for fiscal 2021.
View full Nymox Pharmaceutical company overviewNymox Pharmaceutical annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2021 | 2021-12-31 | −1,529.84% | −1110.10 pp |
| 2020 | 2020-12-31 | −419.74% | −167.83 pp |
| 2019 | 2019-12-31 | −251.90% | +116.52 pp |
| 2018 | 2018-12-31 | −368.42% | — |
Nymox Pharmaceutical quarterly return on equity
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q2.22
Q3.22
Q4.22
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q4 2022 | 2022-12-31 | −920.27% | −398.46 pp |
| Q3 2022 | 2022-09-30 | −597.87% | −493.01 pp |
| Q2 2022 | 2022-06-30 | 2,097.86% | +2267.83 pp |
| Q4 2021 | 2021-12-31 | −521.82% | −511.83 pp |
| Q3 2021 | 2021-09-30 | −104.86% | −82.63 pp |
| Q2 2021 | 2021-06-30 | −169.97% | +1389.71 pp |
| Q1 2021 | 2021-03-31 | −228.69% | −121.72 pp |
| Q4 2020 | 2020-12-31 | −9.99% | +49.08 pp |
| Q3 2020 | 2020-09-30 | −22.24% | +15.01 pp |
| Q2 2020 | 2020-06-30 | −1,559.68% | −1501.41 pp |
| Q1 2020 | 2020-03-31 | −106.97% | −73.39 pp |
| Q4 2019 | 2019-12-31 | −59.07% | −9.31 pp |
| Q3 2019 | 2019-09-30 | −37.25% | +37.37 pp |
| Q2 2019 | 2019-06-30 | −58.28% | +134.70 pp |
| Q1 2019 | 2019-03-31 | −33.58% | — |
| Q4 2018 | 2018-12-31 | −49.76% | — |
| Q3 2018 | 2018-09-30 | −74.62% | — |
| Q2 2018 | 2018-06-30 | −192.98% | — |
Nymox Pharmaceutical return on equity trends
Between the periods ended 2018-12-31 and 2021-12-31, Nymox Pharmaceutical's return on equity decreased from −368.42% to −1,529.84%, a change of −1161.41 percentage points. The latest reported quarter, Q4 2022, shows −920.27%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Nymox Pharmaceutical source filings ↗